newsfilter
← Latest News
Business Wire·

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

Continued advancement across research and development pipeline, with key program updates expected in 2H 2025 Phase 1/2 Duravelo-4 trial for zelenectide pevedotin in NECTIN4-amplified non-small cell lung cancer open